Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by gojotv!on May 04, 2021 8:55am
100 Views
Post# 33122098

RE:RE:RE:RE:Kudos to our much-maligned CEO!

RE:RE:RE:RE:Kudos to our much-maligned CEO!I was there, dude. The Clarus guy put out his analysis on Tuesday, the 6th of April, the day after the Easter weekend. So, the worst of the price drop was indeed caused by his action.
I don't count the 11th hour surge to $1.50ish as the "share price". It was just a few people chasing shares while everyone was holding, waiting for news. The REAL share price was in the $1.20-1.30s, and will get there again,  sooner than later, IMO.
And what did everyone expect as a launch for Aristotle? Expensive and fruitless advertising? Fireworks and dancing girls? Do you really want me to re-post my answer to that idiocy?
This is how you launch a cancer screening test - you make it available on the market. And you save all expenses except to make its availability known to interested medical professionals.
You don't waste money advertising it to the public. They can't get it for themselves.
The course SZLS has taken is very fiscally prudent, yet effective. And the direction they've taken in Covid testing will end up being very lucrative, and an excellent ramp for Aristotle.
Just think! No more financings and dilution!
This is very, very good!


Mermer2328 wrote:
the SP did not drop because of the Analyst downgrade. On April is it dropped by about 40% because of the so called ,half passed Aristotle launch. Way before Noel's downgrade. Get your facts straight before You open your mouth. This new Rexall news might help a bit, but we are after all a cancer company


<< Previous
Bullboard Posts
Next >>